Valuation : Mymetics Corporation

Market Cap 439K 378K 356K 324K 610K 41.64M 613K 4.21M 1.64M 21.18M 1.65M 1.61M 70.24M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.21M 58.52M 53.31M 100M 6.84B 101M 692M 269M 3.48B 271M 265M 11.55B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
5.6
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 2012-11-18
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%+14.29% 45
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+0.80%+46.29%+85.32% 63.6B
+1.31%+1.81%+49.04%+12.07% 25.57B
-1.03%-2.98%-17.27%+430.92% 26.6B
-0.93%-11.79%-0.02%-17.37% 25.52B
-6.09%-11.19%+224.80%+351.08% 18.23B
+1.18%-2.23%+30.87%-19.04% 19.69B
-1.49%-6.35%+7.84%+540.26% 15.16B
+2.08%-1.83%+49.76%+144.86% 13.54B
Average +4.15%-3.46%+106,700.74%+163.18% 27.6B
Weighted average by Cap. -0.14%-2.87%+45.67%+141.38%

Financials

2021 2022
Net sales 430K 371K 349K 318K 598K 40.81M 601K 4.12M 1.61M 20.76M 1.61M 1.58M 68.83M 1.03M 887K 834K 760K 1.43M 97.56M 1.44M 9.86M 3.84M 49.63M 3.86M 3.78M 165M
Net income -4.73M -4.08M -3.84M -3.5M -6.58M -449M -6.61M -45.37M -17.66M -228M -17.76M -17.37M -757M -4.8M -4.14M -3.9M -3.55M -6.68M -456M -6.72M -46.09M -17.94M -232M -18.04M -17.65M -769M
Net Debt 67.1M 57.88M 54.45M 49.6M 93.27M 6.37B 93.78M 644M 251M 3.24B 252M 246M 10.74B 71.68M 61.83M 58.17M 52.99M 99.65M 6.8B 100M 688M 268M 3.46B 269M 263M 11.47B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock